Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Mild and Common-Type COVID-19: A Randomized, Controlled, Multicenter Clinical Study

Table 2

Baseline clinical characteristics.

Symptom	Treatment group; N = 72	Control group; N = 72	value
Fever (N, %)	34 (47.22%)	27 (37.5%)	0.3732
Fatigue (N, %)	20 (27.78%)	19 (26.39%)	0.8971
Cough (N, %)	64 (89.89%)	71 (98.61%)	0.4014
Expectoration (N, %)	29 (40.28%)	34 (47.22%)	0.7338
Short breath (N, %)	10 (13.89%)	8 (11.11%)	0.6232
Chest tightness (N, %)	11 (15.28%)	15 (20.83%)	0.3968
Dyspnea (N, %)	3 (4.17%)	3 (4.17%)	0.9908
Headache (N, %)	3 (4.17%)	3 (4.17%)	1.0000
Nausea (N, %)	5 (6.94%)	7 (9.72%)	0.5507
Vomit (N, %)	5 (6.94%)	5 (6.94%)	1.0000
Diarrhea (N, %)	4 (5.56%)	2 (2.78%)	0.4158
Anorexia (N, %)	6 (8.33%)	8 (11.11%)	0.5860
Dry rale (N, %)	0 (0%)	1 (1.39%)	0.3241
Wet rale (N, %)	1 (1.39%)	1 (1.39%)	1.0000

value, comparison between the treatment group and the control group.  < 0.05 indicates a significant difference.